Скачайте изображение (превью) выбрав качество

320x180 480x360 640x480 1280x720

In this short interview from CRT's 2023 Scientific Sessions, we are joined by Dr Joost Daemen (Thoraxcenter, Erasmus University Medical Center, NL) to outline the FAST III Trial, sponsored by the European Cardiovascular Research Institute. In this study, over 2000 patients were randomized in a 1:1 manner, to vFFR or FFR guided revascularization for the treatment of coronary artery disease. Patients are followed up to 12 months, at which point, the primary endpoints of all-cause death, myocardial infarction and revascularization are analysed.

Questions:
-What was the rationale behind this study?
-What was the patient population, current enrollment status and study design?
-What is the potential impact of the results of this trial?
-What are the next steps for FAST III?

Recorded remotely from Rotterdam, 2023.

Visit Radcliffe Cardiology:

This content is intended for healthcare professionals only.

Radcliffe brings medical knowledge, insight and innovation to life for CV clinicians around the world, using our communications & creative expertise, our platforms and connections across the community to help transform theory into practice faster.

Like us on Facebook:
Follow us on Twitter:

Чтобы скачать видео "CRT 23: vFFr vs FFR Guided Revascularization in Patients with CAD: The FAST III Trial" передвинте ползунок вправо